Importantly, our study has conclusively identified that CCX832 blocks the constrictor effects of chemerin, providing a proof of principle that targeting the chemerin/CMKLR1 axis could deliver a novel therapeutic opportunity in the treatment of hypertension. Here, RARRES2 is linked to hypertensive disorder.